Zinc Chelator Modulation for Oocyte Meiotic Progression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
In assisted reproductive technology, immature oocytes arrested in pre-MII stage are typically discarded due to inability to progress to the fertilizable MII stage, leading to poor fertilization rates, as they require zinc for meiotic maturation and activation, which is insufficiently managed by existing methods.
Innovation Solution
The use of Zn-binding moieties, such as zinc chelators, to modulate zinc availability and facilitate meiotic progression from metaphase I to metaphase II, overcoming meiotic arrests and promoting oocyte activation in fertilized but unactivated oocytes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If zinc is provided to arrested oocytes, then meiotic progression to MII stage is achieved, but uncontrolled zinc levels cause harmful effects
Solution Approach 1:
The patent uses zinc chelators as intermediary molecules that bind zinc ions and deliver them in a controlled manner to the oocyte. These chelators act as mediators between the external zinc source and the oocyte, preventing direct zinc toxicity while ensuring sufficient zinc delivery for meiotic progression. The chelator structure allows selective zinc binding and release at the appropriate intracellular location.
Solution Approach 2:
The patent modifies the zinc delivery system by changing the chemical parameters of zinc delivery - using chelated zinc compounds instead of free zinc ions. This parameter change in the form of zinc delivery (from ionic to chelated form) allows control over zinc release timing and location, transforming the harmful uncontrolled zinc influx into a beneficial controlled process that promotes meiotic maturation without toxicity.
2Reliability
If zinc chelators are used to modulate zinc availability, then meiotic arrest is overcome, but the complexity of the treatment protocol increases
Solution Approach 1:
The zinc chelators are designed to be self-regulating systems that automatically bind zinc ions and release them in response to intracellular conditions. The chelators self-adjust their zinc binding affinity based on the oocyte's zinc status, eliminating the need for external monitoring or complex control mechanisms. This self-service capability simplifies the treatment protocol while maintaining effective zinc delivery for overcoming meiotic arrest.
3Productivity
If zinc levels are increased in fertilized oocytes, then oocyte activation is enhanced, but zinc excess causes harmful effects
Solution Approach 1:
The zinc chelators provide periodic zinc release rather than continuous zinc influx. The chelators bind zinc in the extracellular environment and release it in controlled pulses upon entry into the oocyte or at specific developmental stages. This periodic delivery pattern enhances oocyte activation effectiveness while preventing zinc excess toxicity that would result from continuous zinc supplementation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the reactivation of meiosis in arrested oocytes, increasing fertilization rates by ensuring proper zinc levels for meiotic maturation and activation, thereby producing fertilizable eggs.
Implementation Method 1
Zn-binding moieties (e.g., zinc chelators) are used for reinitiating meiosis or oocyte activation
Implementation Method 2
Zn-binding moieties (e.g., zinc chelators) are used for reinitiating meiosis or oocyte activation
Data Source
AI summary
The present invention provides methods, compositions, and systems for reinitiating meiosis in cells in meiotic arrest and oocyte activation in fertilized, but un-activated, oocytes. In certain embodiments, Zn-binding moieties (e.g., zinc chelators) are used for reinitiating meiosis or oocyte activation.